(Q39472141)

English

Kinetics of antiviral activity and intracellular pharmacokinetics of human immunodeficiency virus type 1 protease inhibitors in tissue culture

scientific article published on November 1999

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

12 September 2017

Kinetics of antiviral activity and intracellular pharmacokinetics of human immunodeficiency virus type 1 protease inhibitors in tissue culture (English)

1 reference

Europe PubMed Central

PMC publication ID

12 September 2017

pharmacokinetics

1 reference

based on heuristic

inferred from title

author name string

M Nascimbeni

1

1 reference

Europe PubMed Central

PMC publication ID

12 September 2017

C Lamotte

2

1 reference

Europe PubMed Central

PMC publication ID

12 September 2017

G Peytavin

3

1 reference

Europe PubMed Central

PMC publication ID

12 September 2017

R Farinotti

4

1 reference

Europe PubMed Central

PMC publication ID

12 September 2017

F Clavel

5

1 reference

Europe PubMed Central

PMC publication ID

12 September 2017

language of work or name

0 references

publication date

1 November 1999

1 reference

Europe PubMed Central

PMC publication ID

12 September 2017

Antimicrobial Agents and Chemotherapy

1 reference

Europe PubMed Central

PMC publication ID

12 September 2017

43

1 reference

Europe PubMed Central

PMC publication ID

12 September 2017

11

1 reference

Europe PubMed Central

PMC publication ID

12 September 2017

2629-2634

1 reference

Europe PubMed Central

PMC publication ID

12 September 2017

Safety, pharmacokinetics, and antiretroviral activity of the potent, specific human immunodeficiency virus protease inhibitor nelfinavir: results of a phase I/II trial and extended follow-up in patients infected with human immunodeficiency virus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=89535

12 September 2017

Protease inhibitors in patients with HIV disease. Clinically important pharmacokinetic considerations

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=89535

12 September 2017

Saquinavir pharmacokinetics alone and in combination with ritonavir in HIV-infected patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=89535

12 September 2017

Antiviral and resistance studies of AG1343, an orally bioavailable inhibitor of human immunodeficiency virus protease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=89535

12 September 2017

Human serum alpha 1 acid glycoprotein reduces uptake, intracellular concentration, and antiviral activity of A-80987, an inhibitor of the human immunodeficiency virus type 1 protease.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=89535

12 September 2017

ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=89535

12 September 2017

Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=89535

12 September 2017

Inhibition of human immunodeficiency virus 1 protease in vitro: rational design of substrate analogue inhibitors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=89535

12 September 2017

Design, activity, and 2.8 A crystal structure of a C2 symmetric inhibitor complexed to HIV-1 protease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=89535

12 September 2017

The postantibiotic effect.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=89535

12 September 2017

Loss of viral fitness associated with multiple Gag and Gag-Pol processing defects in human immunodeficiency virus type 1 variants selected for resistance to protease inhibitors in vivo.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=89535

14 September 2017

Conditional human immunodeficiency virus type 1 protease mutants show no role for the viral protease early in virus replication.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=89535

14 September 2017

Progression of early steps of human immunodeficiency virus type 1 replication in the presence of an inhibitor of viral protease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=89535

14 September 2017

HIV-1 protease inhibitors. A review for clinicians

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=89535

25 September 2017

L-735,524: the design of a potent and orally bioavailable HIV protease inhibitor

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=89535

25 September 2017

HIV-1 Reverse Transcription A Termination Step at the Center of the Genome

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=89535

25 September 2017

Clinical pharmacology of HIV protease inhibitors: focus on saquinavir, indinavir, and ritonavir

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=89535

17 June 2018

Ordered accumulation of mutations in HIV protease confers resistance to ritonavir

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=89535

17 June 2018

A sensitive method for the detection of beta-galactosidase in transfected mammalian cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=89535

17 June 2018

New antiretrovirals and new combinations.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=89535

21 August 2018

A preliminary evaluation of nelfinavir mesylate, an inhibitor of human immunodeficiency virus (HIV)-1 protease, to treat HIV infection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=89535

21 August 2018

Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=89535

21 August 2018

A C2 symmetry-based HIV protease inhibitor, A77003, irreversibly inhibits infectivity of HIV-1 in vitro

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=89535

21 August 2018

Determination of L-735 524, an human immunodeficiency virus protease inhibitor, in human plasma and urine via high-performance liquid chromatography with column switching

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=89535

21 August 2018

Metabolism and disposition of the HIV-1 protease inhibitor ritonavir (ABT-538) in rats, dogs, and humans

1 reference

https://pubmed.ncbi.nlm.nih.gov/10543739

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/10543739

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Postantibiotic suppression of bacterial growth

1 reference

https://pubmed.ncbi.nlm.nih.gov/10543739

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Determination of ritonavir, a new HIV protease inhibitor, in biological samples using reversed-phase high-performance liquid chromatography

1 reference

https://pubmed.ncbi.nlm.nih.gov/10543739

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society-USA Panel

1 reference

https://pubmed.ncbi.nlm.nih.gov/10543739

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

12 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

12 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39472141&oldid=1829796437"